MARILYNE JONES-JENKINS: Open Payments
NPI 1043510423 · HINGHAM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,142 in 124 payments from 12 companies in 2025. Trend: 2023 $3,086 · 2024 $3,421 · 2025 $3,142
Food & beverage: $3,114Education: $29
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 36 | $940 |
| Neurocrine BioSciences, Inc. | 14 | $496 |
| Otsuka America Pharmaceutical, Inc. | 8 | $371 |
| Lundbeck LLC | 14 | $285 |
| Vanda Pharmaceuticals Inc. | 16 | $231 |
| Alkermes, Inc. | 5 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $153 |
| Teva Pharmaceuticals USA, Inc. | 5 | $142 |
| ABBVIE INC. | 10 | $141 |
| Collegium Pharmaceutical, Inc. | 4 | $81 |
Products named: CAPLYTA, REXULTI, INGREZZA, FANAPT, TRINTELLIX, AUSTEDO XR, VRAYLAR, LYBALVI.
Industry payments across MA — which companies pay providers there.
